MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
The primary study objective of safety and tolerability was metSignificant and clinically meaningful improvements from baseline demonstrated for ...
The Pharma Letter7d
MeiraGTx rises on positive study of AAV-GAD for Parkinson’s disease
US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study ...
MeiraGTx Reports Positive AAV-GAD Trial Data For Parkinson's Disease; Stock Climbs
MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...
MedPage Today on MSN18h
MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS Fatigue
A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings ’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD ...
Yahoo Finance8d
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its commercial platform ...
Nasdaq8d
MeiraGTx Reports Positive AAV-GAD Trial Data For Parkinson's Disease; Stock Climbs
AAV-GAD is an investigational gene therapy designed to reprogram dysfunctional brain circuits through the local production of GABA, a chemical neurotransmitter that can help restore more normal ...